TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29846843

Group type: EXPERIMENTAL
Intervention: Velmanase alfa (VA) 1 mg/kg weekly for 52 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (after switch to VA)
Number of subjects: 25
Study: 27277262

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention consisting of six classroom sessions and home visits by trained community health workers.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care plus printed educational materials (Control group).
Number of subjects: 72
Study: 24733910

Group type: EXPERIMENTAL
Intervention: PROSTVAC-VF vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PROSTVAC-VF combined with Quadramet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 100
Study: 23362251

Group type: EXPERIMENTAL
Intervention: Virtual Dolphinarium intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot study for autism screening
Number of subjects: 0
Study: 20840692

Group type: EXPERIMENTAL
Intervention: Single-layer closure of the uterine incision
Number of subjects: 3033

Group type: COMPARATOR
Intervention: Double-layer closure of the uterine incision
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Closure of the pelvic peritoneum
Number of subjects: 3033

Group type: COMPARATOR
Intervention: Nonclosure of the pelvic peritoneum
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Liberal use of a subrectus sheath drain
Number of subjects: 3033

Group type: COMPARATOR
Intervention: Restricted use of a subrectus sheath drain
Number of subjects: 3033
Study: 18837867

Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: IPT
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 344
Study: 17181436

Group type: EXPERIMENTAL
Intervention: Pollinex® Quattro (allergy vaccine)
Number of subjects: 0
Study: 10853311

Group type: EXPERIMENTAL
Intervention: OCT examination of symptom-free fellow eyes with a foveal cyst
Number of subjects: 66

Group type: COMPARATOR
Intervention: OCT examination of symptom-free fellow eyes without a foveal cyst
Number of subjects: 66
Study: 9376452

Group type: EXPERIMENTAL
Intervention: Maintenance nortriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8411909

Group type: EXPERIMENTAL
Intervention: Pirenzepine (20mg administered intravenously immediately after the operation and twice daily from postoperative day 1 until day 7)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (11 cases)
Number of subjects: 21
Study: 3536890

Group type: EXPERIMENTAL
Intervention: Limbitrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study: 31779001

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (5 g/day of fish oil providing 1.9-2.2 g of eicosapentaenoic acid + 1.1 g of docosahexaenoic acid)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS) based on genome-wide association analysis
Number of subjects: 210
Study: 29460817

Group type: EXPERIMENTAL
Intervention: Fish oil liquid softgel (Ocean plus®)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (sunflower oil liquid softgel)
Number of subjects: 120
Study: 27539053

Group type: EXPERIMENTAL
Intervention: Mifepristone followed by oxytocin
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study: 25148234

Group type: EXPERIMENTAL
Intervention: Metreleptin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 20677841

Group type: EXPERIMENTAL
Intervention: Manipulations designed to challenge smoking-related outcome expectancies for pain reduction
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Manipulations designed to enhance pain-related coping
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combination of both manipulations
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 18684437

Group type: EXPERIMENTAL
Intervention: Ruminative self-focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative life events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Momentary ruminative self-focus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trait rumination
Number of subjects: 0
Study: 16320099

Group type: EXPERIMENTAL
Intervention: Talampanel (TLP) 75 mg single oral dose
Number of subjects: 28
Study: 12439210

Group type: COMPARATOR
Intervention: Vitamin A supplementation (not randomized)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: High maternal viral load
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Low CD4 cell count
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: High maternal erythrocyte sedimentation rate (ESR)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Breast lesions during pregnancy
Number of subjects: 1078
Study: 10450459

Group type: EXPERIMENTAL
Intervention: Vignette only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vignette plus two options
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vignette plus the same two options with one positive and one negative consequence
Number of subjects: 0
Study: 8601999

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 167

Group type: COMPARATOR
Intervention: All drugs
Number of subjects: 167
Study: 1934379

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) Q 4 hours
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) Q 6 hours
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) Q 8 hours
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) t.i.d. (0, 6, 12, and 24 hours)
Number of subjects: 44
Study: 6462116

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg twice daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg twice daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30821614

Group type: EXPERIMENTAL
Intervention: Supporting Father Involvement couples group intervention
Number of subjects: 239
Study: 29931434

Group type: EXPERIMENTAL
Intervention: Bedtime Fading with Response Cost (BFRC)
Number of subjects: 3
Study: 27574287

Group type: EXPERIMENTAL
Intervention: Fasting glucose (quartile 3 vs. quartile 1)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Fasting glucose (quartile 4 vs. quartile 1)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Serum insulin (quartile 4 vs. quartile 1)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: HOMA-IR (quartile 4 vs. quartile 1)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Serum insulin (CLD)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: HOMA-IR (CLD)
Number of subjects: 1035
Study: 25054436

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.8 g/day
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study: 22727707

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 19395357

Group type: EXPERIMENTAL
Intervention: Novel computer‐administered measure for malingering detection
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Total completion time and learning curves as genuine impairment indicators
Number of subjects: 114
Study: 17470380

Group type: EXPERIMENTAL
Intervention: Taribavirin 800 mg QD
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Taribavirin 1200 mg QD
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Taribavirin 1600 mg QD
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ribavirin 1000 mg QD
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ribavirin 1200 mg QD
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Taribavirin (any dose)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ribavirin (any dose)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Taribavirin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ribavirin
Number of subjects: 180
Study: 15184351

Group type: EXPERIMENTAL
Intervention: Simvastatin combined with ramipril
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Simvastatin alone
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ramipril alone
Number of subjects: 95

Group type: COMPARATOR
Intervention: Ramipril alone or simvastatin combined with ramipril
Number of subjects: 95
Study: 12100225

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 19
Study: 9676028

Group type: EXPERIMENTAL
Intervention: AML-type chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical trials participation
Number of subjects: 0
Study: 8618802

Group type: EXPERIMENTAL
Intervention: Direct FT4 assay screening for hypothyroidism
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: TSH surge test
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Growth hormone stimulation tests (arginine, insulin, L-dopa)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: TSH samples obtained hourly
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Free thyroxine (FT4) measurement
Number of subjects: 235
Study: 2815979

Group type: EXPERIMENTAL
Intervention: Purified HDCV
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional HDCV
Number of subjects: 77
Study: 770152

Group type: EXPERIMENTAL
Intervention: Sulpiride (300 to 1,200 mg daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Perphenazine (12 to 48 mg daily)
Number of subjects: 82
Study: 31975332

Group type: EXPERIMENTAL
Intervention: 18F-sodium fluoride (18F-NaF) PET imaging
Number of subjects: 128
Study: 31733457

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Childbirth and Parenting Program (MBCP)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Lamaze childbirth class (active control)
Number of subjects: 197
Study: 31931909

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of rifampicin, isoniazid, and pyrazinamide
Number of subjects: 20
Study: 28549220

Group type: COMPARATOR
Intervention: 30‐30 Treadmill
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30‐30 Track
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30‐30 +15% MAV Treadmill
Number of subjects: 15
Study: 26465394

Group type: EXPERIMENTAL
Intervention: Vitamin D levels (25OHD)
Number of subjects: 222
Study: 24084213

Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg oral administration
Number of subjects: 18
Study: 20967458

Group type: EXPERIMENTAL
Intervention: Lemon verbena extract supplementation
Number of subjects: 0
Study: 19487515

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein‐2 matrix
Number of subjects: 463

Group type: COMPARATOR
Intervention: Iliac crest bone‐graft
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 463
Study: 17949681

Group type: EXPERIMENTAL
Intervention: Imagery rescripting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of imagery rescripting and in vivo exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 0
Study: 15714288

Group type: EXPERIMENTAL
Intervention: Double mouse clicks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Single mouse clicks
Number of subjects: 11
Study: 12546485

Group type: EXPERIMENTAL
Intervention: RPMT (Responsivity education for parents and Prelinguistic Milieu Teaching for children)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: RPMT
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 10344035

Group type: EXPERIMENTAL
Intervention: Sarulplase (70-80 mg intravenously, 20 mg bolus followed by 60 mg infusion over 1 hour)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sarulplase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarulplase with heparin (5000 IU bolus)
Number of subjects: 0
Study: 7858592

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA; initial daily dose 1 mg/kg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Methotrexate (MTX; initial weekly dose 7.5 mg)
Number of subjects: 38
Study: 2642486

Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31614332

Group type: EXPERIMENTAL
Intervention: 7-day daily upper-arm remote ischaemic preconditioning (rIPC) (4 × 5 min 220 mmHg, interspaced by 5-min reperfusion)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7-day daily upper-arm remote ischaemic preconditioning (rIPC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study: 28500244

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day for 2 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Estradiol valerate (EV; 2 mg/day for 2 weeks)
Number of subjects: 8
Study: 25159010

Group type: EXPERIMENTAL
Intervention: Resurfacing hemiarthroplasty
Number of subjects: 35

Group type: COMPARATOR
Intervention: Stemmed hemiarthroplasty
Number of subjects: 35
Study: 23426104

Group type: EXPERIMENTAL
Intervention: Reused pacemakers (n=307)
Number of subjects: 603

Group type: COMPARATOR
Intervention: New pacemakers (n=296)
Number of subjects: 603
Study: 19860783

Group type: EXPERIMENTAL
Intervention: Reduced fluence photodynamic therapy (RPDT) + intravitreal triamcinolone acetonide (IVTA) (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard photodynamic therapy (SPDT) + intravitreal triamcinolone acetonide (IVTA) (n = 20)
Number of subjects: 40
Study: 19429918

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg LD/10 mg MD
Number of subjects: 98
Study: 15243280

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7757318

Group type: COMPARATOR
Intervention: 80 mg pentaerithrityl-tetranitrate (PETN) as suspension
Number of subjects: 42

Group type: COMPARATOR
Intervention: 80 mg pentaerithrityl-tetranitrate (PETN) as tablets
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2156475

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (2 mmol/kg body weight over 15 minutes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sodium chloride (equimolar)
Number of subjects: 14
Study: 6773532

Group type: EXPERIMENTAL
Intervention: Clofibate
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 119

Group type: COMPARATOR
Intervention: Antihypertensive drugs (beta-blockers alone or in combination with thiazides)
Number of subjects: 119
Study: 31484666

Group type: EXPERIMENTAL
Intervention: Complete responders (43 participants)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Incomplete responders (28 participants)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Complete responders
Number of subjects: 96

Group type: COMPARATOR
Intervention: Incomplete responders
Number of subjects: 96
Study: 31779675

Group type: EXPERIMENTAL
Intervention: Oral vitamin D supplementation (2000 IU per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No vitamin D supplementation (control group)
Number of subjects: 60
Study: 27984385

Group type: EXPERIMENTAL
Intervention: c‐TBNA without ROSE (TBNA‐NR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: c‐TBNA with ROSE (TBNA‐R)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA without ROSE (EBUS‐NR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA with ROSE (EBUS‐R)
Number of subjects: 80

Group type: COMPARATOR
Intervention: c‐TBNA (TBNA‐NR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: c‐TBNA (TBNA‐R)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA (EBUS‐NR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA (EBUS‐R)
Number of subjects: 80

Group type: COMPARATOR
Intervention: c‐TBNA
Number of subjects: 80
Study: 25040643

Group type: EXPERIMENTAL
Intervention: Nurse-midwife provision of early medical TOP
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Doctor provision of early medical TOP
Number of subjects: 1180
Study: 23633272

Group type: EXPERIMENTAL
Intervention: Red wine (300 mL for 5 days)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 12% ethanol (300 mL for 5 days)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Alcohol drinking group (various alcoholic beverages for 5 days)
Number of subjects: 57
Study: 21336580

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD) with 0 g of l-tryptophan
Number of subjects: 18

Group type: COMPARATOR
Intervention: Balanced condition (BAL) with 1.21 g of l-tryptophan
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acute tryptophan loading (ATL) with 5.15 g of l-tryptophan
Number of subjects: 18
Study: 19586409

Group type: EXPERIMENTAL
Intervention: ASHMI 600 mg (2 capsules) twice daily for 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ASHMI 1200 mg (4 capsules) twice daily for 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ASHMI 1800 mg (6 capsules) twice daily for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ASHMI (all doses combined)
Number of subjects: 20
Study: 17482302

Group type: EXPERIMENTAL
Intervention: High MMCC (Maximal Malignancy Criteria Count in a single node)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low MMCC (Maximal Malignancy Criteria Count in a single node)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pre-treatment hemoglobin levels <12 g/dl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treatment less radical than chemoradiation to 70 Gy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MMCC
Number of subjects: 50
Study: 15636007

Group type: EXPERIMENTAL
Intervention: Nursing interventions
Number of subjects: 0
Study: 11944740

Group type: EXPERIMENTAL
Intervention: Resistance workout
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Speed workout
Number of subjects: 11
Study: 9924296

Group type: EXPERIMENTAL
Intervention: Vertical cup/disc ratio (CDR) using method 1
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vertical cup/disc ratio (CDR) using method 2
Number of subjects: 200
Study: 7801739

Group type: EXPERIMENTAL
Intervention: Viloxazine (VLX, 100 mg b.i.d. for 10 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29781068

Group type: COMPARATOR
Intervention: Lifestyle recommendations (LSR) only
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lifestyle recommendations (LSR) + Pelvic Floor Muscle Training (PFMT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Lifestyle recommendations (LSR) + Pelvic Floor Muscle Training (PFMT) + Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS)
Number of subjects: 67
Study: 29693901

Group type: EXPERIMENTAL
Intervention: Right ventricle apex lead position
Number of subjects: 132

Group type: COMPARATOR
Intervention: Right ventricular outflow tract lead position
Number of subjects: 132
Study: 24253034

Group type: EXPERIMENTAL
Intervention: Tonsillectomy (TE)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 64
Study: 23689848

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN)
Number of subjects: 1372

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1372
Study: 21170107

Group type: EXPERIMENTAL
Intervention: TCI propofol combined with epidural block (group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TCI remifentanil with plasma concentration 4 μg/L and propofol (group B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TCI remifentanil with plasma concentration 7 μg/L and propofol (group C)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TCI propofol and remifentanil (plasma concentration 4 μg/L) with infusion time longer than 4 hours (group D)
Number of subjects: 32

Group type: COMPARATOR
Intervention: All groups (A+B, A+C, A+D)
Number of subjects: 32
Study: 19399385

Group type: EXPERIMENTAL
Intervention: Licensed pharmacological smoking cessation agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel avenues of therapy
Number of subjects: 0
Study: 17101615

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon catheter (3 microg per square millimeter)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Uncoated balloon catheter
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon catheter
Number of subjects: 52
Study: 15666959

Group type: EXPERIMENTAL
Intervention: Collaborative Care, a structured depression treatment program that included planned, proactive and coordinated care with a health care team and informed, activated patients
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 156
Study: 11683830

Group type: EXPERIMENTAL
Intervention: Labeled Magnitude (LM) scale for sensory irritation assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicin challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactic acid challenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recall stimuli related to sting‐type responses
Number of subjects: 0
Study: 9655161

Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 25
Study: 8109113

Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional cholecystectomy (CC)
Number of subjects: 50
Study: 3311905

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg bid)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126